Pfizer trims 2023 revenue outlook as profits tumble

The National Times - Pfizer trims 2023 revenue outlook as profits tumble

ECONOMY 01.08.2023

Pfizer trims 2023 revenue outlook as profits tumble / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File

Pfizer reported a steep drop in profits Tuesday on much lower Covid-related revenues as it curtailed its full-year sales outlook, in part due to tornado damage to a key manufacturing facility.

Change text size:

Profits in the second quarter were $2.3 billion, down 77 percent as revenues fell 54 percent to $12.7 billion.

Quarterly revenues for Pfizer's Covid-19 vaccine and Paxlovid therapeutic were $1.6 billion, far below the $16.9 billion in the year-ago period.

The drugmaker pointed to a "few near-term individual product revenue" challenges as it trimmed its full-year sales forecast.

These include US approval for a drug combination for prostate cancer and a needed recommendation on the Abrysvo vaccine from the US Centers for Disease Control and Prevention.

Pfizer also cited recent tornado damage to a North Carolina manufacturing facility as a drag on near-term results.

The tornado slammed Pfizer's Rocky Mount plant on July 19, which accounts for manufacturing nearly 25 percent of company sterile injectables.

Pfizer said most of the damage was to a warehouse, which stores raw materials and finished medicines awaiting release by quality assurance.

The pharmaceutical giant now expects full-year revenue growth of six to eight percent in 2023, excluding Covid programs. That's down one percent from the prior range.

On Covid, Chief Financial Officer David Denton said the environment "continues to evolve rapidly and remains highly unpredictable," according to a company press release.

"In spite of this uncertainty the company is maintaining its focus on ensuring successful fall vaccinations during the respiratory infection season," Denton said.

Pfizer said its acquisition of biotechnology company Seagen remains on track. The company is in touch with regulators and expects the deal to close in late 2023 or early 2024.

Shares of Pfizer fell 1.2 percent to $35.64 in pre-market trading.

Lewis--TNT

Bilfinger Reports Surge in Orders Amid Profitability Pressures

German industrial services group Bilfinger has reported one of its strongest quarterly order intakes in a decade, with new business rising 25% to £1.2 billion in the third quarter. The surge was driven by energy sector demand, though the company noted that profitability declined as customers delayed investment decisions amid economic uncertainty.

Social Security Tax by State in 2026: Which States Tax Retirement Benefits?

As of 2026, eight U.S. states continue to levy taxes on Social Security retirement benefits, creating a complex financial landscape for retirees. While the Congressional Budget Office estimates that just over half of all beneficiaries will pay federal income tax on their payments, state-level rules vary significantly. Income-based exemptions in these states offer some relief, but the final amount retirees keep depends on a combination of federal thresholds, other retirement withdrawals, and specific state regulations.

Drive Finance Raises EGP 1.5bn via Bond Issuance for Expansion

Drive Finance, the non-bank financial services arm of GB Corp, has successfully closed a EGP 1.5 billion bond issuance with a 13-month maturity. The company stated that the transaction is designed to diversify funding sources and support expansion in its core consumer finance and factoring operations.

First-time boat buyers advised to assess full ownership costs

Buying a first boat is one of those purchases that arrives with a particular quality of excitement that makes careful financial planning feel like an obstacle rather than a preparation. The boat is there, it’s the right size, it’s in reasonable condition, and the idea of being on the water by the weekend is considerably more compelling than the idea of spending another two hours reading about comparison rates.